Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN12299388) titled 'A Phase III trial of inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: Pulmovant, Inc.
Condition:
Pulmonary hypertension associated with interstitial lung disease
Respiratory
Intervention:
The study consists of two periods: a blinded placebo-controlled period (24 weeks) and an extension (beyond 24 weeks).
Participants will be randomized 1:1 to receive mosliciguat or plac...